Ann: FDA grants RPDD to paxaliaib for AT/RT, page-3

From a release by another company in 2020 "To date, 12 out of 25 PRVs received for pediatric indications have been sold for a cumulative sale price of USD 1.6 billion" So now KZA has 2 PRV's worth circa USD$260m for a company with a market cap of AUD$86m. Numbers look good to me. The only reason you wouldn't trade them is if you believe they're better used to bring the drugs to market faster.